Author: Smolders, Elise J; Te Brake, Lindsey Hm; Burger, David M
Title: SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection. Cord-id: ico6qc8m Document date: 2020_6_26
ID: ico6qc8m
Snippet: Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 lopinavir/ritonavir was selected for treatment. The recent publication of Cao et al in the NEJM[1] showed that lopinavir/ritonavir treatment did not accelerate clinical improvement compared with standard of care. This raised the question if we in retrospect could have known this. The aim of this paper is to gather all the available evidence and to comprehensively discuss this issue.
Document: Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 lopinavir/ritonavir was selected for treatment. The recent publication of Cao et al in the NEJM[1] showed that lopinavir/ritonavir treatment did not accelerate clinical improvement compared with standard of care. This raised the question if we in retrospect could have known this. The aim of this paper is to gather all the available evidence and to comprehensively discuss this issue.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date